 HOUSTON, Sept. 01, 2021 GLOBE NEWSWIRE -- Bellicum Pharmaceuticals, Inc. NASDAQ:BLCM, a leader in developing novel, controllable cellular immunotherapies for cancers, and The University of Texas MD Anderson Cancer Center today announced a global option and license agreement covering certain intellectual property and technology rights regarding Bellicums CaspaCIDe inducible caspase-9, or iC9 safety switch and related technologies, and the use of rimiducid, an agent used to activate the safety switch. Under this agreement, MD Anderson will have the option to incorporate CaspaCIDe into certain cellular therapy programs. 